Janux gives conditionally acting therapeutics hope
Early activity of JANX007 in prostate cancer sees Janux stock gain 190%.
Revolution pushes home its pan-KRAS advantage
Not long after starting phase 1, RMC-6236 could be in pivotal trials this year.
Safety remains in focus for Cogent’s bezuclastinib
An “optimised formulation” of bezuclastinib looks promising, but the safety question remains open.
Arcus makes its HIF2α pitch
After living in the shadow of Arcus’s TIGIT project, casdatifan might soon come into its own.
The new normal in US oncology approvals
Nearly two thirds of key oncology filings are expedited; and what about the ones that aren’t?
Mesothelin lives on
Work targeting mesothelin, and some other antigens that have hitherto disappointed, continues.
